Centre for Ophthalmology, Eberhard-Karls University of Tuebingen, Germany.
Acta Ophthalmol. 2011 Feb;89(1):17-24. doi: 10.1111/j.1755-3768.2009.01617.x.
To evaluate whether tumour therapy for malignant uveal melanoma leads to a shedding of melanoma cells into the systemic circulation.
Ninety-four peripheral blood samples from 81 patients with malignant uveal melanoma were collected before and after different tumour therapies and the number of circulating melanoma cells (CMCs) was investigated (seven patients with enucleation, 49 patients with stereotactic radiotherapy, 19 patients with endoresection of the tumour, 15 patients with ruthenium-brachytherapy and four patients with transpupillary thermotherapy). A cellular approach was used to detect CMCs through an immunocytological assay with tumour cell enrichment by immunomagnetic cell sorting. The number of CMCs was analysed further according to specific patient characteristics, tumour parameters and the development of metastasis.
There was no significant difference between the number of CMCs before and after the different therapies (p = 0.78). There was also no significant association between established prognostic parameters of primary uveal melanoma and the detection of CMCs (all p >0.05). The number of CMCs was not related to the development of metastasis in a short median follow-up time of 16 months (p > 0.05).
No changes in CMC values were observed before and after different tumour therapies. In the majority of cases therapy does not lead to a shedding of detectable melanoma cells into the systemic circulation.
评估恶性葡萄膜黑色素瘤的肿瘤治疗是否会导致黑色素瘤细胞脱落进入体循环。
收集 81 例恶性葡萄膜黑色素瘤患者 94 例外周血样本，分别在不同肿瘤治疗前后进行检测，并对循环黑色素瘤细胞（CMCs）的数量进行调查（7 例眼球摘除术、49 例立体定向放疗、19 例肿瘤内切除术、15 例钌近距离放射治疗和 4 例经瞳孔热疗）。采用细胞免疫化学法，通过免疫磁细胞分选对肿瘤细胞进行富集，检测 CMCs。根据患者的具体特征、肿瘤参数和转移的发展，进一步分析 CMCs 的数量。
不同治疗前后 CMCs 的数量无显著差异（p = 0.78）。原发性葡萄膜黑色素瘤的既定预后参数与 CMCs 的检测也无显著相关性（均 p >0.05）。在中位随访时间为 16 个月的短时间内，CMCs 的数量与转移的发展无关（p >0.05）。
不同肿瘤治疗前后 CMC 值无变化。在大多数情况下，治疗不会导致可检测的黑色素瘤细胞脱落进入体循环。
